USFDA issues seven observations to Glenmark Pharmaceuticals’ Baddi unit

28 Nov 2017 Evaluate

The United States Food & Drug Administration (USFDA) has issued seven observations to Glenmark Pharmaceuticals through form 483 for its Baddi unit. The USFDA had conducted audit at Baddi unit from November 6, 2017 to November 11, 2017.

The company is in the midst of providing a comprehensive response to the observations and would be replying to the USFDA shortly on the observations. Currently, the Baddi unit contributes approximately 10 percent of the revenue of US sales.

Glenmark’s current portfolio consists of 129 products authorized for distribution in the US marketplace and 58 ANDA’s pending approval with the USFDA.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×